Robert John Amato, DO

Professor and Division Director
Department of Internal Medicine and Oncology
The University of Texas Medical School
Houston, TX 77030, USA



Dr. Amato is the Director and a Professor of the Division of Oncology at the University of Texas Health Science Center at Houston and Director of the University of Texas Memorial Hermann Cancer Center. He obtained his Doctor of Osteopathic Medicine from the University of North Texas before becoming a fellow in Medical Oncology at MD Anderson Cancer Center.
Dr. Amato is one of the world’s leading experts in the treatment of genitourinary cancer. Early in his career, his research helped make testicular cancer a highly treatable disease. His current research focuses on molecular-targeted therapeutics to halt the progression of metastatic kidney and prostate cancers, the further development of immunotherapies with a primary focus on vaccine and immune therapy, and determining how elements from his current studies may be used in the treatment of bladder and testicular cancer.

Research Interest

His research interests include: Urologic oncology, Prostate cancer, Renal cell cancer, Bladder cancer, Biomarkers, Personalized treatment, Prognostic models and Tumor molecular alterations.

Scientific Activities


• (1986) The University of Texas MD Anderson Cancer Center Clifton D. Howe Award for Clinical Excellence
• (1992) 2000 Notable American Men
• (1992) Whos Who Among Rising Young Americans
• (2000) The University of Texas M.D. Anderson Cancer Center Medical Oncology Fellows Teacher of the Year Award
• (2004) The National Registry of Whos Who in Medical Sciences Education


• American Association for Cancer Research
• American Association for the Advancement of Science
• American Society of Clinical Oncology
• American Medical Association
• American Osteopathic Association
• Association of Clinical Research Professionals
• Cell Stress Society International
• European Association of Urology
• Harris County Medical Society
• Kidney Cancer Association
• University of Texas MD Anderson Cancer Center Associates
• Texas Medical Oncology Foundation
• The Society of Urologic Oncology
• New York Academy of Sciences
• International Cytokine Society
• European Society for Medical Oncology
• European Society of Cancer Immunology and Immunotherapy
• Academy of Pharmaceutical Physicians and Investigators
• International Society for Biological Therapy of Cancer
• American Society of Clinical Oncology


1. Amato RJ, Saxena S, Stepankiw M, Ramirez P. Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments. Cancer Investigation. 2012. doi:10.3109/07357907.2013.764564
2. Amato RJ, Melnikova V, Zhang Y, et al. EpCAM-positive circulating tumor cells as a predictive biomarker in prostate cancer patients. Urology. 2012.
3. Amato RJ, Hotte S, Nemunaitis J, Belanger K. MG98, a second generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma. Cancer Investigation. 2012; 30: 415-421. doi:10.3109/07357907.2012.675381
4. Amato RJ, Wilding G, Bubley G, et al. Safety and Preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clinical Genitourinary Cancer. 2012.
5. Amato RJ, Stepankiw M. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncology. 2012; 8(3): 231-237. doi:10.2217/fon.12.7
6. Amato RJ, Flaherty AL, Stepankiw M. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clinical Genitourinary Cancer. 2011; 10(1): 26-31. doi:10.1016/j.clgc.2011.11.002